Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant in South Korea met both primary and …